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Synthesis of Sulfo-Sialic Acid 
Analogues: Potent Neuraminidase 
Inhibitors in Regards to Anomeric 
Functionality
Christopher J. Vavricka1,2, Chiaki Muto1, Tomohisa Hasunuma2, Yoshinobu Kimura1, Michihiro 
Araki2, Yan Wu3, George F. Gao3, Hiroshi Ohrui4, Minoru Izumi1 & Hiromasa Kiyota 1
The design, synthesis and application of N-acetylneuraminic acid-derived compounds bearing anomeric 
sulfo functional groups are described. These novel compounds, which we refer to as sulfo-sialic acid 
analogues, include 2-decarboxy-2-deoxy-2-sulfo-N-acetylneuraminic acid and its 4-deoxy-3,4-
dehydrogenated pseudoglycal. While 2-decarboxy-2-deoxy-2-sulfo-N-acetylneuraminic acid contains 
no further modifications of the 2-deoxy-pyranose ring, it is still a more potent inhibitor of avian-origin 
H5N1 neuraminidase (NA) and drug-resistant His275Tyr NA as compared to the oxocarbenium ion 
transition state analogue 2,3-dehydro-2-deoxy-N-acetylneuraminic acid. The sulfo-sialic acid analogues 
described in this report are also more potent inhibitors of influenza NA (up to 40-fold) and bacterial NA 
(up to 8.5-fold) relative to the corresponding anomeric phosphonic acids. These results confirm that this 
novel anomeric sulfo modification offers great potential to improve the potency of next-generation NA 
inhibitors including covalent inhibitors.
Neuraminidase (NA, EC 3.2.1.18), also referred to as sialidase, is a retaining glycosidase that hydrolyzes 
α-ketosidic linkages to sialic acids. Common substrates recognized by NA contain terminal N-acetylneuraminic 
acid (Neu5Ac, NANA) or N-glycolylneuraminic acid (Neu5Gc, NGNA) with an α2-3 or α2-6 ketosidic bond 
to galactose. NA is found in many types of pathogens including Trypanosoma cruzi, Clostridium perfringens, 
Streptococcus pneumoniae, Vibrio cholerae, mumps virus, parainfluenza virus and influenza virus. By destroying 
sialic acid-containing glycosides, NA facilitates the movement of pathogens through biological environments 
rich in sialic acid receptors, including mammalian tissues and mucus. Therefore inhibition of NA can hinder 
the spread of sialic acid binding pathogens, and NA inhibitors offer great potential as anti-microbial agents. 
In the case of sialic acid binding viruses, NA also facilitates the release of progeny virions from infected cells. 
Accordingly, NA inhibitors have been especially successful as anti-influenza pharmaceuticals1, 2.
The first generation of NA inhibitors was based upon Neu5Ac and its dehydrated product 2,3-dehydro-2-d
eoxy-N-acetylneuraminic acid (Neu5Ac2en or DANA). Currently, all clinically used NA inhibitors contain an 
anomeric carboxy group, which forms strong electrostatic interactions with three structurally conserved arginine 
residues in the NA active site (Fig. 1)1. Despite a lack of sequence identity among NAs from unrelated species, 
many active site structural features, including the triarginyl cluster, are highly conserved across all known NAs. 
For example, in the case of influenza A NA, a glycoside hydrolase family 34 member, this triarginyl cluster con-
sists of Arg118, Arg292 and Arg371 (Fig. 1)3. In the case of Clostridium perfringens NanI NA, a glycoside hydro-
lase family 33 member, the arginine triad consists of Arg266, Arg555 and Arg615.
Replacement of the inhibitor carboxy group with a phosphono group has previously been reported to improve 
NA inhibitory activity and therefore phosphonic acid analogues of sialic acid are currently under development4–10. 
This increase in potency has been attributed to stronger electrostatic interactions of the anomeric phosphono 
with the conserved active site NA triarginyl cluster (Fig. 1)5, 6.
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Based upon the higher acidity and electronegativity of sulfo relative to carboxy and phosphono functional 
groups, we predicted that sialic acid anomeric sulfonic acid analogues, which we refer to as sulfo-sialic acid ana-
logues, should form the strongest electrostatic interactions with the conserved NA active site triarginyl cluster 
(Fig. 1). This strategy has been considered in an in silico analysis, which also indicated that the sulfo group should 
produce the strongest binding inhibitors11. Yet, the actual synthesis of sulfo-sialic acid analogues is quite challeng-
ing and has remained unreported. In fact, with exception to 2-amino and 2-acetamido anomeric sulfonates, no 
2-deoxy sugar with an anomeric sulfo group has been reported to our knowledge12, 13.
We first became interested in the synthesis of sulfo-sialic acid analogues during our research on covalent NA 
inhibitors, which have utilized an electronegative 3-fluoro group to destabilize formation of oxocarbenium ion 
transition states (Fig. 1A)3. In addition to enhancing electrostatic interactions with the triarginyl cluster, a strong 
electron withdrawing sulfo group might also destabilize oxocarbenium ion formation. In this report we reveal the 
first synthesis of sulfo-sialic acid analogues and their application as potent NA inhibitors.
Results and Discussion
Sulfo-sialic acid analogues were synthesized via oxidation of a mixture of acetylthio intermediates according to 
Fig. 2. Neu5Ac (1)-derived peracetylated octoses 2a and 2b, first reported by Potter and von Itzstein, were selected 
as the substrate for sulfur addition14. The decarboxylated Neu5Ac derivatives 2a and 2b were synthesized based 
on the method of Shie et al. with modifications5.
Nucleophilic substitution of the 2 anomeric position with HSAc was mediated by either BF3·Et2O or TMSOTf, 
using CH3CN, CHCl3, or 1,2-dichloroethane (1,2-DCE) as solvent (Table 1). Although our original intention was 
to produce only 3, during NMR analysis of the acetylthio reaction products, a surprisingly large peak was always 
observed at 5.80 ppm, with coupling to another singlet at 6.27 ppm. These NMR peaks were later attributed to 
H-1, H-2 and H-3 of the 2,3-unsaturated pseudoglycal 4b, similar to compounds resulting from the Ferrier rear-
rangement of glycals in which the axial orientation of the anomeric acetylthio group is also preferred15, 16. The 
axial orientation of the acetylthio group of 4b is indicated by a lack of NOE correlation between H-1 and H-5. 
The structure of 4b was further supported by high-resolution mass spectrometry (HRMS), and characterization 
of the oxidation products 6b and 8b. The dominance of the axial acetylthio orientation of this pseudoglycal could 
be explained by the anomeric effect. Less polar reaction conditions were used to produce a higher ratio of 4b to 3 
(Table 1). More polar reaction conditions could be used to weaken the anomeric effect and increase the propor-
tion of equatorial acetylthio compound 3a (Table 1).
Oxidation of the acetylthio functionality of 3 and 4 to the sulfo functionality was achieved using excess Oxone 
(potassium peroxymonosulfate, KHSO5· 0.5KHSO4· 0.5K2SO4) in AcOH buffered with KOAc, based upon the 
method of Reddie17–19. Workup was somewhat difficult due to the presence of excess salt, so the procedure was 
modified with NH4OAc in place of KOAc for the oxidation of 3 to 5, which appeared to be quantitative. Yields for 
the oxidation of 4 to 6 were low due to concurrent oxidation of the pseudoglycal ring double bond by the excess 
Oxone. During HRMS analysis of polar Oxone oxidation products, negative ions m/z 452.0826 (6 + O), m/z 
454.0985 (6 + O + 2H) and m/z 470.0949 (6 + 2O + 2H) were detected, indicating that 6 was further oxidized. 
Sulfonates 5a and 5b could also be converted to the corresponding methyl esters by reaction with trimethylsi-
lyldiazomethane, a toxic reagent that should be handled with caution. Active sulfo-sialic acid analogues, 7a, 7b 
and 8b were obtained after deprotection of the precursors in the presence of NaOH.
The structures of sulfo-sialic acid analogues 5-8 were determined using HRMS,1H, GCOSY, NOESY and13C 
data. H-1, H-2 and H-5 are all shifted downfield in the axial anomeric sulfonates 5b and 7b relative to the equa-
torial isomers 5a and 7a, which is also observed in 2, 3, and the phosphonic acid analogues of 5 and 74, 5. The 
H-1 to H-2 coupling constants of 5a, 5b, 7a and 7b match those of the corresponding phosphonic acids and 
Figure 1. NA binding comparison of anomeric carboxy, anomeric phosphono and anomeric sulfo analogues 
of N-acetylneuraminic acid. (A) The carboxylate of 3-fluoro-Neu5Ac covalently bound to influenza A/
RI/5+/1957(H2N2) NA (N2) NA (PDB ID: 45H2)3. (B) An equatorial phosphonate Neu5Ac analogue 
(eqPO3H) bound to influenza A/Tokyo/3/67(H2N2) NA with the phosphorus atom colored orange (PDB 
ID: 1INX)6. (C) Predicted binding of the equatorial sulfo-sialic acid analogue 7a to N2 with the sulfur atom 
colored yellow (based on PDB ID: 45H2). The structure of 7a was modeled in the N2 active site using Molecular 
Operating Environment (MOE). Electrostatic interactions with the anomeric functional groups are shown as 
dashed lines with stronger predicted ionic interactions colored orange and red.
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carboxylic acids as well4, 5, 20. A clear H-1 to H-5 NOE correlation is observed in the equatorial sulfo compound 
7a. In contrast, the lack of any NOE correlation between H-1 and H-5 in 8b is consistent with the axial anomeric 
functional group orientations of 4b, 6b and 8b. A clear H-1 to H-2 NOE correlation in 8b further supports the 
equatorial orientation of H-1. Synthesis of psuedoglycals with anomeric sulfones has also been reported with axial 
anomeric stereoselectivity21. Isomerization of the anomeric position was never observed for any of the sulfo-sialic 
acid analogues.
Due to the high electronegativity of the sulfo group, the diagnostic H-1, H-2, H-5 and C-1 chemical shifts of 
5 and 7 are shifted downfield relative to the corresponding carboxylic acids and phosphonic acids (Table 2). This 
observance of a strong electron-withdrawing inductive effect of the anomeric sulfo group supports our hypothesis 
that sulfo-sialic acid analogues will be useful for the development of next-generation covalent NA inhibitors3.
In order to assess the relative effectiveness of sulfo-sialic acid analogues, the anomeric phosphonic acids cor-
responding to 7a (eqPO3H, ePANA) and 7b (axPO3H, aPANA) were synthesized based upon the methods of Shie 
et al. with modifications5. Inhibition of influenza A/Anhui/1/2005 (H5N1) NA (N1), A/RI/5+/1957(H2N2) NA 
(N2), Clostridium perfringens NanJ NA (CpNA) and Streptococcus 6646K NA (StrepNA), was quantified using a 
fluorogenic assay based upon the method by Potier et al. with modifications22. Inhibition of influenza and bacte-
rial NA by sulfo-sialic acid analogues confirms that the sulfo group enables more potent NA inhibition relative to 
the analogous phosphonic acids (Table 3, Fig. 3). The NA inhibitory activity of axPO3H was difficult to quantify 
due to its low potency. For inhibition of influenza N2, the equatorial anomeric sulfonate 7a was 40-fold more 
Figure 2. Synthesis of sulfo-sialic acid analogues. α-Anomers 2a, 3a, 5a and 7a are in the R anomeric 
configuration with equatorial anomeric functional groups, and β-anomers 2b, 3b, 4b, 5b, 6b, 7b and 8b are in 
the S anomeric configuration with axial anomeric functional groups.
2 Lewis Acid HSAc Solv. Time Temp. Yield 3a:3b:4b
426 µmol, 115 mM TMSOTf, 290 mM, 2.5 eq. 737 mM, 6.4 eq. CH3CN 19 h. −20 °C - r.t. 44% 33:36:31
1.97 mmol, 94 mM BF3·Et2O, 684 mM, 7.2 eq. 746 mM, 7.9 eq. 1,2-DCE 45 h. 0 °C - r.t. 71% 17:54:29
673 µmol, 22 mM BF3·Et2O, 53 mM, 2.4 eq. 56 mM, 2.5 eq. 1,2-DCE 11 h. 0 °C - r.t. 40% 6:28:66
Table 1. Reaction conditions and yields for synthesis of acetylthio glycoside 3 and acetylthio pseudo-glycal 4b.
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potent than eqPO3H. The axial anomeric sulfonates 7b and 8b were also more potent N2 inhibitors relative to 
eqPO3H. In the case of CpNA inhibition, 7a was 8.5-fold more potent than eqPO3H.
The sialic acid anomeric sulfo modification is advantageous in terms of drug resistance because of the essential 
role of the triarginyl binding site for natural NA substrate binding. Substitution of Arg118, Arg292 and Arg371 
is known to result in impaired viral fitness due to decrease in NA activity and substrate affinity24. Although the 
Arg292Lys substitution is well documented, we showed that it results in an 88-fold Km increase and a decrease in 
the enzymatic activity of H7N9 NA25. One of the most common forms of NA inhibitor resistance is caused by a 
His275Tyr substitution, which confers a high level of resistance to oseltamivir and moderate resistance to peram-
ivir24, 26. Consistent with the results for A/RI/5+/1957(H2N2) NA, 7a inhibits H5N1 N1 and its drug-resistant 
His275Tyr form at the same level (Table 3, Fig. 4), demonstrating the effectiveness of sulfo-sialic acid analogues 
against highly-prevalent drug-resistant NA and highly-pathogenic avian-origin NA.
Sialic acid anomeric phosphonic acid analogues were first reported by Walliman and Vasella in 19904. The 
long delay in the synthesis of sulfo-sialic acid analogues might be explained by challenges with the current syn-
thesis. Some difficulty includes the similar chromatographic mobility of the anomeric acetoxy and anomeric 
acetylthio intermediates, the precise conditions of the acetylthio oxidation, difficulty in sulfo protection, and high 
water solubility of the protected sulfo-sialic acid analogues.
The clinically used NA inhibitors zanamivir, oseltamivir, peramivir and laninamivir inhibit influenza NA at a 
low nanomolar level1. Despite having a lower potency, the sulfo-sialic acid analogue 7a contains no other struc-
tural improvements and is still a more potent inhibitor of influenza NA than the oxocarbenium ion transition 
state analogue Neu4Ac2en (N2 IC50: 19 μm)27. Therefore, our sulfo modification in combination with other mod-
ifications may offer potential to produce sub-nanomolar level NA inhibitors. In conclusion, this report proves the 
concept that sulfo-sialic acid analogues are the most potent NA inhibitors with regards to anomeric functionality. 
Further development of novel sulfo-sialic acid based inhibitors with increased potency and efficacy is currently 
underway.
Methods
NMR Analysis. Compounds were analyzed using Varian 400 MHz and 600 MHz systems (now Agilent) at the 
Okayama University Collaboration Center, and also using a JEOL ECZ400 spectrometer at the Kobe University 
Department of Chemical Science and Engineering. Measurements were taken with 2-4 dissolved in CDCl3, and 
5-8 dissolved in CD3OD. NMR chemical shifts (δ) are provided in parts per million (ppm).1H-NMR coupling 
constants (J) are listed in Hz. Residual peaks of chloroform (7.26 ppm) and methanol (3.31 ppm) were used 
as1H-NMR references. The residual peaks of chloroform (77.0 ppm) and methanol (49.0 ppm) were also used 
as13C-NMR references. For 2D experiments, the standard pulse sequences programmed into the Varian NMR 
systems were used. 2D-NOESY experiments were performed at room temperature with a spectral width of 9615.4 
Hz (sw), an acquisition time of 0.15 seconds (at), 2844 data points (np), a filter bandwidth of 4000 Hz (fb), a relax-
ation delay of 2.000 seconds (d1), 4 transients (nt), 128 or 200 experiments (ni), a pulse width of 9.700 or 10.900 
microseconds (pw) and a mixing time 0.500 seconds (mixN).
C-1 Anomeric C-2 H-1 Anomeric H-2ax H-2eq H-5 Solvent
7a 87.0 36.4 4.28 1.79 2.45 3.63 CD3OD
7b 86.7 34.3 4.70 1.92 2.62 4.25 CD3OD
eqPO3H 73.6 36.2 3.75 1.70 2.24 3.49 CD3OD
axPO3H 71.9 34.4 4.25 1.94 2.36 3.93 CD3OD
eqCO2H* 76.8 37.8 3.87 1.56 2.36 3.58 D2O
axCO2H* 74.8 35.2 4.44 1.87 2.56 3.62 D2O
Table 2. Diagnostic 13C and 1H chemical shifts (ppm) of sulfo-sialic acid analogues compared to the 
corresponding phosphonic acids4, and carboxylic acids20. *Sialic acid numbering has been changed to assign the 
anomeric position as 1.
7a 7b 8b eqPO3H
N1 Ki 1.62 (1.08–2.27) — — —
N1-His275Tyr Ki 2.07 (1.63–2.62) — — —
N2 Kia 2.47 (1.95–3.14) 33.5 (26.0–43.1) 88.1 (72.8–107) 103 (82.6–128)
N2 IC50 8.86 (6.99–11.3) 120 (93.0–155) 316 (260–384) 368 (296–458)
CpNA IC50 37.5 (31.2–45.0) — — 320 (221–460)
StrepNA IC50 3.74 (2.56–5.43) — — —
Table 3. Ki (inhibitory constant) and IC50 (50% inhibition constant) values for the inhibition of N1, N2, CpNA, 
and StrepNA. All values are given in μm units and 95% confidence intervals are listed inside parenthesis. 
aInfluenza N2 Ki values were estimated using the Cheng-Prusoff equation (Ki = IC50/(1 + [S]/Km))23 with the N2 
Km previously determined as 46.5 μM3. Dashes (−) indicate that inhibition was not determined.
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High Resolution Mass Spectrometry (HRMS). Compound identities were confirmed with HRMS, 
which was performed using an Agilent 6520 Accurate-Mass Q-TOF at the Okayama University Collaboration 
Center.
Neuraminidase Inhibition. Inhibition of neuraminidase (NA) activity was quantified using a fluoro-
genic assay based upon the method by Potier et al.22 with modifications. 4-methylumbelliferyl-α-d-Neu5Ac 
Figure 3. Sulfo-sialic acid analogue NA inhibition. Inhibition of N2 (A), CpNA (B) and StrepNA (C) hydrolysis 
of 4-methylumbelliferyl-Neu5Ac with 7a (blue), 7b (red), 8b (green) and eqPO3H (magenta). Error bars 
indicate standard error and inhibitor concentrations (x-axis) units are μM.
Figure 4. Inhibition of avian-origin H5N1 N1 by sulfo-sialic acid analogue 7a. (A) 7a inhibits wildtype N1 with 
an inhibitory constant (Ki) of 1.62 μM. (B) Predicted binding of 7a to the wildtype N1 active site. (C) 7a inhibits 
His275Tyr oseltamivir-resistant N1 with a similar potency to that of wildtype N1. (D) Predicted binding of 7a 
to the His275Tyr N1 active site shows that the 7a glycerol side chain maintains the same interactions with the 
Glu276 side chain. Key residues relating to His275Tyr drug resistance are shown inside transparent spheres. 
Electrostatic interactions of the inhibitor sulfo group and glycerol moiety are indicated by dashed lines, with 
stronger ionic interactions colored orange. The binding analysis was performed with MOE based on the 
structure of A/Vietnam/1203/04 (H5N1) NA (PDB ID 3CKZ)26.
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(4-MU-Neu5Ac) substrate was utilized at a final concentration of 120 μm for inhibition of N2 and Streptococcus 
6646K NA (Amsbio). For inhibition of Clostridium perfringens NanJ NA (Sigma) the 4-MU-Neu5Ac concentra-
tion was 60 μm when using 7a and 120 μm when using eqPO3H. For IC50 determination, 5–8 inhibitor concentra-
tions were used with 1–4 replicates for each condition. For N1 Ki determination, 5 inhibitor concentrations and 
3 substrate concentrations were used. NA and inhibitor were pre-incubated for 20 minutes at room temperature 
before starting each assay with addition of 4-MU-Neu5Ac. Fluorescence of liberated 4-methylumbelliferyl (Ex. 
355–360 nm, Em. 460 nm) was detected at room temperature using a Thermo Scientific Varioskan™ Flash or a 
Molecular Devices SpectraMax Paradigm microplate reader. IC50 values and confidence intervals were calculated 
by analyzing inhibition data using the ‘log(inhibitor) vs. response (three parameters)’ function of Prism 7 soft-
ware. N1 Ki values were calculated using the Michaelis-Menten function of Prism 7, and N2 Ki values were cal-
culated using the Cheng-Prusoff equation23. A/Anhui/1/2005 (H5N1) NAs were purchased from Sino Biological. 
Influenza A/RI/5+/1957(H2N2) NA was produced according to our previously reported methods3.
Modeling Sulfo-Sialic Acid Analogue Binding. Sulfo-sialic acid analogue binding to NA active sites 
was modeled with Molecular Operating Environment (MOE) version 2016.0802 from Chemical Computing 
Group. The structure of 7a was built in the A/RI/5+/1957(H2N2) N2 (PDB ID: 45H2) and A/Vietnam/1203/04 
(H5N1) His275Tyr N1 (PDB ID: 3CKZ) active sites using the MOE Builder function. This was followed by run-
ning Structure Preparation, Protonate 3D, and Energy Minimization with the Amber10:EHT forcefield. Binding 
of 7a to wildtype N1 was performed in the same manner as that of the N1-His275Tyr structure (PDB ID: 3CKZ) 
after substitution of Try275 with histidine using the MOE Protein Builder function.
Synthesis of 4-Acetamido-3,6,7,8-tetra-O-acetyl-1-acetylthio-1,2,4-trideoxy-d-glycero-d-galacto-octopyranose 
(3 )  and  4-Acetamido-6 ,7 ,8- tr i -O-acety l -1-acety lthio-2 ,3-didehydro-1 ,2 ,3 ,4- te tradeoxy-d- 
glycero-d-galacto-octopyranose (4). The known compound 4-acetamido-1,3,6,7,8-penta-O-acetyl-2,4-dideoxy-d- 
glycero-d-galacto-octopyranose (2) was synthesized based upon the methods of Shie et al.5 with a 49% yield. 2 
(0.4-1 g, 0.69-2 mmol) was dissolved in distilled 1,2-dichloroethane (1,2-DCE) or CH3CN dried with excess 
molecular sieves. After cooling, HSAc and Lewis acid (BF3·Et2O or TMSOTf) were carefully added to the solution 
according to Table 1. The reaction was kept under an atmosphere of N2 and the temperature was slowly raised 
to room temperature. After completion, the organic layer was combined with CHCl3 and washed with aqueous 
solutions of NaHCO3 and NaCl. The washed organic layer was dried over MgSO4, filtered through diatomaceous 
earth and evaporated under reduced pressure. Acetylthio reaction products 3 and 4 were isolated using normal 
phase column chromatography with EtOAc as the mobile phase. When using the polar conditions of Table 1 entry 
1, 63 μmol 3a was obtained from 426 μmol 2 (14% yield); when using the non-polar conditions of Table 1 entry 
2, 766 μmol 3b was obtained from 1.97 mmol 2 (39% yield); and when using the more non-polar conditions of 
Table 1 entry 3, 176 μmol 4b was obtained from 673 μmol 2 (26% yield).
3a (α-Anomer): Rf = 0.4 (EtOAc); 1H-NMR (400 MHz, CDCl3): 1.89 (s, 3H, NHAc), 2.0-2.13 (4s, 12H, 
4 OAc), 2.34 (s, 3H, SAc), 3.77 (dd, 1H, J5,4 = 10.4, J5,6 = 2.4, H-5), 4.0 (m, 1H, H-4), 4.36 (dd, 1H, J8,7 = 2.5, 
J8,8′ = 12.5, H-8), 5.36 (dd, 1H, J6,5 = 2.4, J6,7 = 7.1, H-6); + ESI HRMS calcd for C20H29NNaO11S: 514.1359, found: 
m/z 514.1393 [M + Na]+.
3b (β-Anomer): Rf = 0.4 (EtOAc); 1H-NMR (600 MHz, CDCl3): 1.89 (1s, 3H, NHAc), 1.98–2.12 (4s, 12H, 4 
OAc), 2.16–2.19 (ddd, 1H, H-2ax), 2.30–2.36 (m, 1H, H-2eq), 2.37 (s, 3H, SAc), 3.91 (dd, 1H, J5,4 = 10.4, J5,6 = 1.9, 
H-5), 4.00–4.05 (m, 2H, H-4, H-8) 4.27 (dd, 1 H, J8′,7 = 2.9, J8′,8 = 12.6, H-8′), 5.00 (ddd, 1H, J3,2eq = 4.7, J = 10.3, 
J = 11.7, H-3), 5.12 (ddd, 1H, J7,6 = 7.2, J7,8 = 6.3, J7,8′ = 2.9, H-7), 5.31 (dd, 1H, J6,5 = 1.9, J6,7 = 7.2, H-6), 5.41 (d, 
1H, JNH,4 = 10, NH), 6.14 (d, 1H, J1,2ax = 4.7, H-1); 13C-NMR (150 MHz, CD3OD): 20.67, 20.69, 20.8, 20.9, 21.05, 
23.15 (C=OCH3), 36.1 (C-2), 50.1, 62.1, 67.3, 69.6, 69.9, 72.5 (C-3–C-8), 79.0 (C-1), 169.4, 170.0, 170.13, 170.16, 
170.5, 171.0 (C=OCH3); + ESI HRMS calcd for C20H29NNaO11S: 514.1359, found: m/z 514.1393 [M + Na]+.
4b (β-Anomer): Rf = 0.4 (EtOAc):1H-NMR (600 MHz, CDCl3): 1.98–2.12 (4s, 12H, 4 C=OCH3), 2.35 (s, 
3H, SAc) 3.83 (dd, 1H, J5,4 = 10, J5,6 = 1.8, H-5), 4.11 (dd, 1H, J8,7 = 5.7, J8,8′ = 12.5, H-8), 4.30 (dd, 1H, J8′,7 = 2.6, 
J8′,8 = 12.6, H-8′), 4.50 (t, 1H, J4,3 = 9.8, J4,5 = 9.8, H-4), 5.21 (ddd, 1H, J7,6 = 7.8, J7,8 = 5.6, J7,8′ = 2.6, H-7), 5.31 (dd, 
1 H, J6,5 = 1.8, J6,7 = 7.8, H-6), 5.53 (d, 1H, JNH,4 = 9.4, NH) 5.80 (s, 2H, H-2, H-3) 6.27 (s, 1H, H-1); 13C-NMR (150 
MHz, CD3OD): 20.70, 20.73, 20.95, 21.1, 23.4 (5 C=OCH3), 43.6, 62.1, 67.4, 69.3, 70.1 (C-4–C-8), 78.7, (C-1), 
125.7, 131.1 (C-2, C-3), 169.6, 169.8, 170.2, 170.53, 170.58 (5 C=OCH3); + ESI HRMS calcd for C18H25NNaO9S: 
454.1148, found: m/z 454.1177 [M + Na]+.
Synthesis of 4-Acetamido-3,6,7,8-tetra-O-acetyl-1-sulfo-1,2,4-trideoxy-d-glycero-d-galacto-octopyranose (5). 3 
(427 mg, 869 mmol, 3a:3b = 2:7) and 4b (307 mg, 711 mmol) were dissolved in AcOH. NH4OAc (1.0 g, 13 mmol, 
8.2 eq.) and Oxone (3.67 g, 11.9 mmol, 7.5 eq.) were mixed in to form a slurry. After 21 hours, MeOH was added 
to the reaction mixture, which was then filtered through a fritted funnel. The crude mixture was evaporated under 
reduced pressure, followed by purification of 5a and 5b (525 mg, 5a:5b = 2:7, quantitative yield) with normal 
phase chromatography using a gradient of EtOAc and EtOH.
5a (α-Anomer): Rf = 0.39 (EtOAc:EtOH = 2:1); 1H-NMR (400 MHz, CD3OD): 1.8–2.0 (m, 1H, H-2ax) 1.85 
(s, 3H, NHAc), 1.97–2.08 (4s, 12H, OAc), 2.49 (ddd, 1H, J2eq,1 = 2.1, J2eq,2ax = 12.6, J2eq,3 = 5.1, H-2eq), 3.81 (dd, 
1H, J5,4 = 10.4, J5,6 = 2.3, H-5), 3.97 (ddd, 1H, J4,3 = 10.4, J4,5 = 10.4, J4,NH = 10.4, H-4), 4.21 (dd, 1H, J8,7 = 6.3, 
J8,8′ = 12.3, H-8), 4.26 (dd, 1H, J1,2ax = 11.8, J1,2eq = 2.1, H-1), 4.53 (dd, 1H, J8′,7 = 2.8, J8′,8 = 12.4, H-8′), 5.00 
(ddd, 1H, J3,2ax = 11.3, J3,2eq = 5.1, J3,4 = 10.2, H-3), 5.30 (ddd, 1H, J7,6 = 6.2, J7,8 = 6.2, J7,8′ = 2.7, H-7), 5.39 (m, 
1H, H-6); 13C-NMR (150 MHz, CD3OD): 20.69, 20.79, 20.82, 20.82, 22.7 (5 C=OCH3), 33.6 (C-2), 50.5, 63.2, 
69.4, 72.6, 73.2, 78.6 (C-3–C-8), 87.3 (C-1), 171.7, 171.8, 172.0, 172.5, 173.4 (5 C=OCH3); -ESI HRMS calcd for 
C18H26NO13S−: 496.1130, found: m/z 496.1142 [M − H]−.
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5b (β-Anomer): Rf = 0.4 (EtOAc:EtOH = 2:1);1H-NMR (600 MHz, CD3OD): 1.84 (s, 3H, NHAc) 1.9–2.1 (m, 
1H, H-2ax), 1.97, 2.00, 2.07, 2.08 (4s, 12H, OAc), 2.68 (ddd, 1H, J2eq,1 = 1.0, J2eq,2ax = 13.9, J2eq,3 = 5.4, H-2eq), 3.96 
(t, 1H, J4,3 = 10.3, J4,5 = 10.3, H-4), 4.12 (dd, 1H, J8,7 = 5.3, J8,8′ = 12.6, H-8), 4.42 (dd, 1H, J8′,7 = 2.9, J8′,8 = 12.3, 
H-8′), 4.66 (d, 1H, J1,2ax = 6.7, H-1), 4.77 (dd, 1H, J5,4 = 10.4, J5,6 = 2.2, H-5), 5.21 (ddd, 1H, J7,6 = 7.8, J7,8 = 5.1, 
J7,8′ = 2.6, H-7), 5.39 (dd, 1H, J6,5 = 2.2, J6,7 = 7.8, H-6), 5.58 (ddd, 1H, J3,2ax = 10.5, J3,2eq = 5.4, J4,5 = 10.5, H-3); 
13C-NMR (150 MHz, CD3OD): 20.7, 20.8, 20.9, 21.3, 22.6 (5 C=OCH3), 31.5 (C-2), 50.7, 63.1, 69.1, 71.0, 71.0, 
73.0 (C-3–C-8), 85.8 (C-1), 171.7, 172.0, 172.2, 172.6, 173.5 (5 C=OCH3); -ESI HRMS calcd. for C18H26NO13S−: 
496.1130, found: m/z 496.1142 [M − H]−.
Synthesis of 4-Acetamido-6,7,8-tri-O-acetyl-1-sufo-2,3-didehydro-1,2,3,4-tetradeoxy-d-glycero-d- 
galacto-octopyranose (6). 4b (76 mg, 176 μmol) was dissolved in AcOH (3 mL). KOAc (Wako, 190 mg, 1.94 
mmol, 9.85 eq.) and Oxone (378 mg, 1.23 mmol, 6.24 eq.) were mixed in to form a slurry. After 4.66 hours MeOH 
was added to the reaction mixture, which was then filtered through a fritted funnel. The crude mixture was evap-
orated under reduced pressure, followed by purification of 6b (10.5 μmol, 6% yield) using normal phase column 
chromatography.
6b (β-Anomer): Rf = 0.39 (EtOAc:EtOH = 2:1);1H-NMR (600 MHz, CD3OD): 1.92, 2.01, 2.08 (3s, 12H, 4 Ac), 
4.21 (dd, 1H, J8,7 = 5.5, J8,8′ = 12.4, H-8), 4.52 (m, 2H, H-4, H-8′), 4.60 (m, 1H, H-5), 4.91 (m, 1H, H-1), 5.28 (ddd, 
1H, J7,6 = 7.4, J7,8 = 5.3, J7,8′ = 2.6, H-7), 5.40 (dd, 1H, J6,5 = 2.1, J6,7 = 7.1, H-6), 5.83 (dt, 1H, J3,1 = 2.1, J3,2 = 10.2, 
J3,4 = 2.1, H-3), 6.11 (dt, 1H, J2,1 = 2.9, J2,3 = 10.1, J2,4 = 2.9, H-2);13C-NMR (150 MHz, CD3OD): 20.7, 21.3, 22.6, 
23.7 (4 C=OCH3), 43.9, 63.1, 69.2, 71.5, 71.7 (C-4–C-8), 86.1 (C-1), 124.8, 131.9 (C-2, C-3), 171.6, 172.2, 172.6, 
173.2 (4 C=OCH3); -ESI HRMS calcd for C16H22NO11S−: 436.0919, found: m/z 436.0929 [M − H]−.
Preparation of 4-Acetamido-1-sulfo-1,2,4-trideoxy-d-glycero-d-galacto-octopyranose (7) and 4-Acetamido-1-sufo-
2,3-didehydro-1,2,3,4-tetradeoxy-d-glycero-d-galacto-octopyranose (8). To prepare active sulfo-sialic acid ana-
logues, 5a (10 mg), 5b (10 mg), and 6b (4 mg) were treated with a solution of 0.1 m NaOH in MeOH. After 
deprotection reached completion, the pH was neutralized with AcOH and solvent was evaporated under reduced 
pressure resulting in quantitative final product yields. 7a, 7b and 8b were purified to homogeneity using an 
Inertsil® ODS-3 semi-preparative HPLC column (GL Sciences) with a mobile phase of 10–15% MeOH supple-
mented with NH4OAc.
7a (α-Anomer): Rf = 0.6 (acetone:butan-1-ol:H2O = 70:27:3); 1H-NMR (600 MHz, CD3OD): 1.79 (ddd, 1H, 
J2ax,1 = 12, J2ax,2eq = 12, J2ax,3 = 12, H-2ax), 2.00 (s, 3H, Ac), 2.45 (ddd, 1H, J2eq,1 = 1, J2eq,2ax = 14, J2eq,3 = 5.5, H-2eq), 
3.47 (dd, 1H, J6,5 = 0.9, J6,7 = 8.8, H-6), 3.62–3.65 (m, 2H, H-5, H-8), 3.74–3.89 (m, 4H, H-3, H-4, H-7, H-8′), 4.28 
(dd, 1H, J1,2ax = 11.7, J1,2eq = 2.1, H-1); 13C-NMR (150 MHz, CD3OD): 22.8 (C=OCH3), 36.4 (C-2), 53.7, 64.9, 
70.2, 70.8, 71.4, 78.6 (C-3–C-8), 87.0 (C-1), 174.8 (C=OCH3); -ESI HRMS calcd for C10H18NO9S−: 328.0708, 
found: m/z 328.0727 [M − H]−.
7b (β-Anomer): Rf = 0.65 (acetone:butan-1-ol:H2O = 70:27:3); 1H-NMR (600 MHz, CD3OD): 1.92 (ddd, 1H, 
J2ax,1 = 7, J2ax,2eq = 14, J2ax,3 = 10.9, H-2ax), 2.01 (s, 3H, Ac), 2.62 (ddd, 1H, J2eq,1 = 1, J2eq,2ax = 14, J2eq,3 = 5.5, H-2eq), 
3.44 (dd, 1H, J6,5 = 1.2, J6,7 = 9.1, H-6), 3.57–3.60 (m, 1H, H-8), 3.75 (t, 1H, J4,3 = 10.1, J4,5 = 10.1, H-4), 3.79–3.84 
(m, 2H, H-7, H-8′), 4.25 (dd, 1H, J5,4 = 10.6, J5,6 = 1.5, H-5), 4.40 (ddd, 1H, J3,2ax = 10.3, J3,2eq = 5.4, J3,4 = 10.3, 
H-3), 4.70 (d, 1H, J1,2ax = 6.7, H-1); 13C-NMR (150 MHz, CD3OD): 22.6 (C=OCH3), 34.3 (C-2), 54.3, 64.6, 67.2, 
70.2, 72.4, 74.3 (C-3–C-8) 86.7 (C-1), 175.3 (C=OCH3); -ESI HRMS calcd for C10H18NO9S−: 328.0708, found: 
m/z 328.0727 [M − H]−.
8b (β-Anomer): Rf = 0.6 (acetone:butan-1-ol:H2O = 70:27:3); 1H-NMR (600 MHz, CD3OD): 1.98 (s, 3H, 
Ac), 3.50 (dd, 1H, J6,5 = 1.5, J6,7 = 9.1, H-6), 3.62 (dd, 1 H, J8,7 = 6.2, J8,8′ = 11.4, H-8), 3.83 (dd, 1H, J8′,7 = 2.9, 
J8′,8 = 11.4, H-8′), 3.92 (ddd, 1H, J7,6 = 9.1, J7,8 = 6.2, J7,8′ = 2.9, H-7), 4.35 (dd, 1H, J5,4 = 9.5, J5,6 = 1.6, H-5), 4.68 
(dddd, 1H, J4,1 = 2.3, J4,2 = 2.3, J4,3 = 2.3, J4,5 = 9.5, H-4), 4.96 (ddd, 1H, J1,2 = 2.6, J1,3 = 2.6, J1,4 = 2.6, H-1), 5.93 
(dt, 1H, J3,1 = 2.1, J3,2 = 10.3, J3,4 = 2.1, H-3), 6.13 (dt, 1H, J2,1 = 2.8, J2,3 = 10.3, J2,4 = 2.8, H-2); 13C-NMR (150 
MHz, CD3OD): 22.6 (C=OCH3), 44.6, 64.9, 70.1, 72.4, 73.0 (C-4–C-8), 86.3 (C-1), 124.9, 132.0 (C-2, C-3), 173.9 
(C=OCH3); -ESI HRMS calcd for C10H16NO8S−: 310.0602, found: m/z 310.0578 [M − H]−.
Data Availability. The datasets generated and analyzed during the current study are available from the cor-
responding authors upon reasonable request.
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